Neuraxis (NRXS) vs Precision Optics (POCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Neuraxis (NRXS) has outperformed Precision Optics (POCI) over the past year, gaining 128.0% versus a gain of 5.5%. Neuraxis is the larger company by market cap ($87.0 million vs $50.3 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | POCI |
|---|---|---|
| Share price | $6.93 | $4.58 |
| Market cap | $87.03M | $50.26M |
| 1-day change | +2.36% | -1.82% |
| YTD return | +52.64% | +9.31% |
| 1-year return | +127.96% | +5.53% |
| 5-year return | — | -30.61% |
| Forward P/E | — | 152.67 |
| EPS (TTM) | $-0.78 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $6.15 |
| 52-week low | $2.21 | $3.55 |
| Distance from 52-week high | -25.72% | -25.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.73% | +74.67% |
| Average volume | 108.37K | 52.42K |
| Shares outstanding | 12.56M | 10.97M |
| Employees | 24 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed POCI by 122.4 percentage points over the past year.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
About Precision Optics
POCI stock →Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 108 employees
NRXS vs POCI FAQ
Which is bigger, Neuraxis or Precision Optics?
Neuraxis (NRXS) is larger, with a market capitalization of $87.03M compared with $50.26M for Precision Optics (POCI).
Which stock has performed better over the past year, NRXS or POCI?
NRXS returned +127.96% over the past 12 months, compared with +5.53% for POCI (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and Precision Optics in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.